[I. Docetaxel must be reconsidered in light of high cost-effectiveness in the treatment of prostate cancer].

[I. Docetaxel must be reconsidered in light of high cost-effectiveness in the treatment of prostate cancer].

Gan To Kagaku Ryoho. 2016 Jan;43(1):45-9

Authors: Kimura G

PMID: 26955664 [PubMed - in process]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/1TvUG5a
via IFTTT